Tecartus (brexucabtagene autoleucel) for the Treatment of Mantle Cell Lymphoma (MCL)

Tecartus™ (brexucabtagene autoleucel, formerly KTE-X19) is the first and only approved CAR T cell therapy for treating relapsed or refractory mantle cell lymphoma (MCL). Credit: Kite, a Gilead Company.



  • Tecartus
  • Tecartus
  • Tecartus